Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
The Federal Trade Commission (FTC) filed a lawsuit Friday against three major prescription drug benefit managers (PBMs) and ...
U.S. Federal Trade Commission Chair Lina Khan on Friday welcomed that companies are weighing antitrust considerations early ...
A Federal Trade Commission (FTC) report found that social and video streaming services pose serious privacy risks, especially ...
The Washington Post on MSN1d
FTC sues pharmacy insurance managers, alleging unfair drug pricesThe Federal Trade Commission sued the three dominant pharmacy-benefit managers ... of a product that is essential for people with diabetes. According to the FTC, the three largest PBMs — CVS ...
At this week’s National Advertising Division Annual Conference, FTC Commissioner Melissa Holyoak and FTC Bureau of Consumer Protection Director ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback